CLASSIFICATION: SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM)
ACTIVE SUBSTANCE: TAMOXIFEN CITRATE
FORM: 100 TABLETS × 20 MG
ACTIVE HALF-LIFE: ~5–7 DAYS
DOSAGE: MEN 10–40 MG/DAY
ACNE: NO
WATER RETENTION: REDUCED
HIGH BLOOD PRESSURE (HBP): LOW RISK
HEPATOTOXICITY: LOW
AROMATIZATION: BLOCKED
MANUFACTURER: BRITISH DRAGON
Tamoxifen 20 mg is a pharmaceutical-grade selective estrogen receptor modulator (SERM) widely used by bodybuilders, athletes, and fitness enthusiasts for estrogen control and post-cycle therapy (PCT). Tamoxifen plays a crucial role in protecting against estrogen-related side effects while supporting hormonal balance during recovery phases.
Tamoxifen works by selectively blocking estrogen receptors in certain tissues, particularly breast tissue, without significantly reducing circulating estrogen levels. This mechanism makes it highly effective for preventing and managing gynecomastia while preserving estrogen's beneficial roles in joint health, mood, and cardiovascular function.
Unlike aromatase inhibitors, Tamoxifen does not stop estrogen production. Instead, it prevents estrogen from binding to receptors where unwanted effects may occur. This distinction makes Tamoxifen a cornerstone compound during post-cycle therapy rather than an on-cycle estrogen suppression agent.
The pharmacological properties and clinical applications of Tamoxifen are well documented. A comprehensive overview of its mechanism of action can be found via the National Library of Medicine (PubMed).
The primary effect of Tamoxifen 20 mg is estrogen receptor blockade in targeted tissues. This helps prevent the development of gynecomastia and reduces estrogen-related discomfort during and after anabolic steroid cycles.
During post-cycle therapy, Tamoxifen supports recovery by improving the body's hormonal signaling environment. While it does not directly stimulate testosterone production, it enhances the effectiveness of natural recovery processes when estrogen feedback is properly controlled.
Users commonly report improved well-being, stabilized mood, and reduced post-cycle crashes when Tamoxifen is incorporated into a structured recovery plan.
Typical Tamoxifen dosages range from 10 mg to 40 mg per day, depending on individual needs and cycle history. Many users follow a tapered approach during PCT, starting at 20–40 mg daily and gradually reducing the dosage over several weeks.
Because Tamoxifen has a long active half-life, consistent once-daily dosing is sufficient. Higher dosages do not necessarily accelerate recovery and may increase the likelihood of side effects.
Dosage should always be tailored to the compounds used during the cycle and the user's individual recovery response.
Tamoxifen is most commonly used during post-cycle therapy following suppressive anabolic steroid cycles. It is often combined with Clomiphene to create a comprehensive PCT protocol that addresses both estrogen receptor control and testosterone recovery.
After injectable testosterone cycles such as Testabol Enanthate, Tamoxifen is typically introduced once hormone levels begin to decline, helping stabilize estrogen activity during recovery.
Tamoxifen may also be used preventively during cycles that involve estrogen-sensitive compounds like Oxydrol, particularly if early signs of gynecomastia appear.
Tamoxifen is not intended to replace aromatase inhibitors during high-estrogen cycles but serves as an essential tool for estrogen receptor management and recovery.
Tamoxifen is generally well tolerated when used at recommended dosages. Some users may experience mild side effects such as headaches, nausea, or temporary visual disturbances.
These effects are usually dose-dependent and subside as the body adapts or when dosage is adjusted. Long-term misuse or excessive dosing is not advised.
Tamoxifen does not exhibit significant hepatotoxicity and is considered liver-safe for most users when used responsibly.
British Dragon Tamoxifen 20 mg tablets are manufactured under strict quality control standards to ensure accurate dosing and consistent effectiveness. Each bottle contains 100 tablets, making it suitable for multiple PCT cycles or long-term estrogen management planning.
Tamoxifen remains one of the most trusted and widely used SERMs in performance-focused hormone management protocols.
Tamoxifen is used to block estrogen receptors, prevent gynecomastia, and support post-cycle therapy.
No, Tamoxifen is a SERM that blocks estrogen receptors but does not reduce estrogen production.
Yes, it may be used if gynecomastia symptoms appear, but it is most commonly used during PCT.
PCT protocols typically last 4–6 weeks, depending on cycle length and compounds used.
No, Tamoxifen is not considered hepatotoxic when used responsibly.
Please log in to write TAMOXIFEN 20 MG (100 TABS) review.
CLASSIFICATION: SELECTIVE ANDROGEN RECEPTOR MODULATOR
ACTIVE SUBSTANCE: TAMOXIFEN CITRATE
FORM: 100 TABLETS (40 MG/TABLET)
ACTIVE HALF-LIFE: ~ 5–7 DAYS
DOSAGE: 20–40 MG DAILY
ACNE: LOW
WATER RETENTION: NONE
HIGH BLOOD PRESSURE (HBP): LOW RISK
HEPATOTOXICITY: LOW
AROMATIZATION: NONE
MANUFACTURER: STEALTH LABS USA
LABORATORY TESTED: VIEW LAB RESULTS
SHIPPED WITHOUT LABEL!
CLASSIFICATION: SERM (SELECTIVE ESTROGEN RECEPTOR MODULATOR)
ACTIVE SUBSTANCE: TAMOXIFEN CITRATE
FORM: 100 TABLETS x 20 MG
ACTIVE HALF-LIFE: ~5–7 DAYS
DOSAGE: MEN 10–40 MG/DAY
ACNE: UNLIKELY
WATER RETENTION: NONE
HIGH BLOOD PRESSURE (HBP): NO
HEPATOTOXICITY: LOW
AROMATIZATION: BLOCKED AT RECEPTOR LEVEL
MANUFACTURER: AXIOLABS
THIS KIT CONTAINS:
1 x DIANABOL 20 MG by Dragon Pharma (Size: 100 tabs)
2 x HCG 5000 IU, 2 ml vial by Dragon Pharma
1 x NOLVADEX 20mg by Dragon Pharma (Size: 100 tabs)
1 x ARIMIDEX 1 MG by Dragon Pharma (Size: 100 tabs)
1 x CLOMID 50mg by Dragon Pharma (Size: 100 tabs)
1 x DECA 500 by Dragon Pharma (Size: 1 vial)
3 x SUSTANON 270, 10ml vial by Dragon Pharma (Size: 3 vials)
CLASSIFICATION: SERM (SELECTIVE ESTROGEN RECEPTOR MODULATOR)
ACTIVE SUBSTANCE: TAMOXIFEN CITRATE
FORM: 100 TABLETS x 20 MG
ACTIVE HALF-LIFE: 5–7 DAYS
DOSAGE: 20–40 MG/DAY (PCT)
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HBP): NO
HEPATOTOXICITY: LOW
AROMATIZATION: NO
MANUFACTURER: KALPA PHARMACEUTICALS